Medical product and technology company ConvaTec Group PLC said on Monday it has made several senior appointments as a result of changes to its organisational structure.
From January 1, 2018 the group’s four franchises will he headed by Franchise Presidents who will report directly to the Chief Executive Officer, and will responsible for the development and delivery of its strategic plans across all its target markets, as well as marketing and research & development within their franchises.
Peter Byloos will be appointed as head of Advanced Wound Care. He will be joining from European investment company Gimv, where he is partner for healthcare for nearly three years since the start of 2015.
Erik Zimmer will continue as vice president & general manager of Ostomy Care, with an appointment of a president for the franchise to be made in due course.
ConvaTec will promote current Interim President of Europe, Middle East & Africa Frank Gehres as president of Continence and Critical Care, with Mads Haugaard reporting to him as vice president & general manager.
Gehres will be replaced as president of Europe, Middle East & Africa by Kjersti Grimsrud, who will be joining from rapid point-of-care diagnostics tests manufacturer Alere Inc, where she was president of Europe & Middle East and president International for three and a half years since 2014.
John Lindskog will continue as president with responsibility over the Infusion Devices franchise.
In addition, ConvaTec will appoint Sean McGrath as executive vice president of global human resources, joining from the World Bank Group where he was vice president of human resources for five years since 2012. He will be replacing Marc Reuss, who has held the role for two years since 2015.
Also, President of Global Franchises and Innovation Symeria Hudson, will be leaving with effect at the end of 2017, after nearly two years in the role since March 2016.
“These important changes to our organisation will drive a greater focus on the leadership of our Franchises and on their performance as business units of ConvaTec, as well as providing better leverage of our strong new product pipeline. I am confident that this new structure will enable us to drive increased value from our leading market positions across each of the businesses,” said Chief Executive Officer Paul Moraviec.
Shares in ConvaTec were up 1.2% at 201.90 pence on Monday.
By Dayo Laniyan
Source: Alliance News
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.
